AWARD A LETTER CONTRACT FOR RADX TECH - OASIS DIAGNOSTICS TO COMPLETE THE VALIDATION, APPROVAL, AND PRODUCTION PROCESSES IN ORDER TO SCALE UP CAPACITY

与 RADX TECH - OASIS DIAGNOSTICS 签订书面合同，完成验证、批准和生产流程，以扩大产能

• 批准号: 10505989
• 负责人: PAUL SLOWEY
• 金额: $ 767.92万
• 依托单位: OASIS DIAGNOSTICS CORPORATION
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-01-08 至 2022-01-07
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10505989
• 关键词: Businesses; COVID-19; COVID-19 test; COVID-19 testing; Cells; Collection; Contracts; Devices; Diagnostic; Employee; Equipment; Funding; Goals; Human Resources; Letters; Oral; Process; Production; RADx; RADx Tech; RNA; Resources; Saliva; Series; Specimen; Standardization; Technology; Testing; Time; Validation; innovation; manufacturing scale-up; programs; salivary assay; scale up; tool; viral RNA

Oasis Diagnostics provides a series of innovative tools for standardized saliva acquisition including devices specific for cell free RNA / viral RNA that are ideally suited for COVID-19 testing on difficult saliva specimens. These collection tools [Pure•SAL, Super•SALâ„¢, Micro•SAL and SimplOFy] in particular are agnostic to the test being used and are already being used by many companies developing oral / saliva based tests for COVID-19. Oasis is a small business with under 20 employees and has been requested by companies developing COVID-19 to scale up manufacturing in order to produce volumes in excess of 100,000 Units of these technologies on a daily basis.  In order to be able to meet this goal, Oasis Diagnostics requires additional manpower, equipment and additional resources that it does not have at the present time.  As a result Oasis is seeking funding through the RADx Program to facilitate large scale manufacturing to meet the rapidly growing market for saliva collection technologies

Oasis Diagnostics提供了一系列用于标准化唾液采集的创新工具，包括专用于无细胞RNA /病毒RNA的设备，非常适合对困难的唾液标本进行COVID-19检测。特别是这些采集工具[PureSAL、SuperSAL、MicroSAL和SimplOFy]与所使用的检测无关，并且已经被许多开发基于口腔/唾液的COVID-19检测的公司所使用。Oasis是一家员工不到20人的小型企业，开发COVID-19的公司要求Oasis扩大生产规模，以便每天生产超过100，000单位的这些技术。为了能够实现这一目标，Oasis Diagnostics需要额外的人力，因此，Oasis正在通过RADx计划寻求资金，以促进大规模生产，满足唾液收集技术快速增长的市场需求。